Question Bank › Promise already turning into fact

Promise already turning into fact

Promise already turning into fact: management shows the thing it told investors was coming is now measurably arriving, a

Calls Tested
309
Answered YES
46
Hit Rate
14.9%
rare by design

CollPlant Biotechnologies Ltd. (CLGN) — this company's answers

NO on the Q4 2023 call 2024-04-04 F
The model's full reasoning — Q4 2023 call → NO我们根据提供的财报电话会议记录,判断管理层是否指出了之前告诉投资者预期的增长性发展,并展示了当前实际活动证明该发展正在按计划或更快实现,同时表示该发展仍处于早期阶段。 关键点: - 管理层提到了与AbbVie的合作,特别是真皮填充剂产品。在2023年6月,他们宣布达到了一个重要里程碑,触发了1000万美元的付款。在本次电话会议上,他们提到该产品“现在处于临床开发阶段”,并且AbbVie在财报电话会议上表示预期美学市场增长,填充剂市场在多个季度下滑后预计回升。但管理层没有明确说“我们之前告诉过你们这个增长会到来”,而是描述了当前进展。 - 关于乳房植入物,他们提到正在进行大型动物研究,并计划在2024年第四季度和2025年第一季度报告结果。这似乎是新进展,但之前是否告诉过投资者?在2023年1月他们宣布了第一次大型动物研究结果,所以这是后续研究。但管理层没有明确说“我们之前预期这个研究会在此时进行”。 - 关于gut-on-a-chip,他们决定暂停,这不是增长性发展。 - 关于ESG,不是增长性发展。 核心问题:管理层是否明确指出了一个之前设定的增长预期,并展示了当前实际活动证明该预期正在实现,同时表示仍处于早期? 在电话会议中,Yehiel Tal说:“Throughout 2023 we made significant progress with AbbVie to advance this candidate towards commercialization. In June of last year, we announced the achievement of an important milestone under this collaboration, which triggered a $10 million payment from AbbVie to CollPlant.” 然后说“The dermal filler product candidate, which is our top focus, is now in the clinical phase of development”。这暗示了进展,但并没有明确说“我们之前告诉过你们这个产品会在2023年进入临床”之类的。实际上,在之前的电话会议中,他们可能已经提到过预期。但本次电话会议中,他们没有明确引用之前的预期。 另外,关于乳房植入物,他们说“We have begun an additional large animal study with clinically relevant commercial size implants.” 并说“We look forward to reporting results from this animal studies in the fourth quarter of this year and the first quarter of 2025.” 这似乎是新研究,但之前是否预期过?在2023年1月他们宣布了第一次研究结果,所以这是后续。但管理层没有说“正如我们之前所说,我们计划进行这项研究”。 关键点:管理层是否明确指出了一个之前设定的增长预期?在电话会议中,他们提到了“as we said”之类的吗?没有。他们只是描述了当前进展。 此外,关于AbbVie合作,他们提到“In their full year and fourth quarter conference call, AbbVie stated that they expect meaningful growth in the aesthetics market and that importantly, a ramping up is now anticipated after multiple quarters of decline in the U.S. filler market.” 这是引用AbbVie的预期,而不是CollPlant自己的预期。CollPlant没有说“我们之前告诉过你们这个市场会回升”。 因此,没有明确的三部分模式:没有明确指回之前设定的预期,没有展示当前实际活动作为确认(虽然提到了临床阶段,但那是进展,不是确认之前预期),也没有说“仍处于早期”之类的。 实际上,关于乳房植入物,他们说“We cannot stress enough the improvement that a regenerative breast implant could provide”但那是宣传,不是确认。 所以,答案应为NO。 但让我们再仔细看:管理层是否在说“我们之前告诉过你们这个产品会进入临床”?没有。他们只是陈述事实。 因此,答案是否定的。

← Back to the full CLGN analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management point to a growth-bearing development in its business that IT HAD PREVIOUSLY TOLD INVESTORS TO EXPECT — and demonstrate, with real current-period activity, that this development is NOW ACTUALLY ARRIVING at or beyond the pace management had indicated, while ALSO conveying that the development is still early, with most of its contribution ahead? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent three-part pattern: (1) A PRIOR EXPECTATION MANAGEMENT ITSELF HAD SET. Management refers back — explicitly or in plain substance — to something about the growth of the business it had previously communicated or anticipated: a ramp, launch, recovery, adoption, expansion, capacity fill, customer conversion, or similar forward development it told investors was coming. The reference may be phrased in many ways ('as we said last quarter...', 'consistent with what we laid out...', 'we told you this would begin...', 'in line with the plan we described...'), so long as it concerns the business growing or inflecting — not a cost program, financing step, or routine housekeeping. (2) CURRENT REALITY IS NOW CONFIRMING IT. Management points to concrete activity in the just-reported period or happening now — actual orders, customers, volumes, shipments, deployments, utilization, openings, sign-ups, revenue from the new thing, or equivalent real events — as evidence that the anticipated development is materializing on schedule or faster/bigger than indicated. The confirmation must rest on things that already happened, described with enough substance that the arrival is observable rather than asserted. (3) MANAGEMENT SAYS IT IS STILL EARLY. Management conveys, directly or plainly in substance, that what has arrived so far is only the beginning of the development — the ramp is in its early innings, contribution to reported results is still small relative to what the same trajectory delivers ahead, further stages are already scheduled or in motion — so the reported numbers understate where the confirmed trajectory is already heading. The essence is ONE phenomenon: a management team that made a growth claim, is now standing in front of evidence that the claim is coming true, and is telling investors the verified trajectory has much further to run. The industry, the nature of the development, and the form of the evidence may vary widely. Answer NO if management describes promising developments with no indication it had previously set that expectation — a fresh announcement is not verification. NO if the look-back is only to beating financial guidance or consensus numbers, with no underlying operating development being confirmed. NO if the previously-promised item is a cost reduction, restructuring, refinancing, or housekeeping matter rather than a growth-bearing development. NO if the confirmation rests on pipeline, interest, letters of intent, or expectations rather than real current activity. NO if management indicates the development is now substantially complete or fully reflected in results, with little still ahead. NO if management is explaining that the anticipated development is late, smaller than expected, or being walked back. NO if the pattern appears only in an analyst's question or summary that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
MCD McDonald's Corporation Q2 2024 2024-07-29 D
AES The AES Corporation Q1 2024 2024-05-03 C+
ASB Associated Banc-Corp Q1 2024 2024-04-25 A
DUOT Duos Technologies Group, Inc. Q4 2023 2024-04-01 F
HP Helmerich & Payne, Inc. Q1 2024 2024-01-30 C
SCPH scPharmaceuticals Inc. Q3 2023 2023-11-08 B
SITM SiTime Corporation Q2 2023 2023-08-02 C+
DKS DICK'S Sporting Goods, Inc. Q4 2022 2023-03-07 B
XHR Xenia Hotels & Resorts, Inc. Q2 2022 2022-08-05 A
BRKL Brookline Bancorp, Inc. Q2 2022 2022-07-30 B+
UPWK Upwork Inc. Q2 2022 2022-07-27 C+
KD Kyndryl Holdings, Inc. Q4 2021 2022-03-01 C+
EXP Eagle Materials Inc. Q3 2022 2022-01-27 B
WES Western Midstream Partners, LP Q3 2018 2018-10-31 D
MAS Masco Corporation Q3 2018 2018-10-30 C
AU AngloGold Ashanti's Q2 2018 2018-08-20 B
MKC McCormick & Company, Incorporated Q2 2018 2018-06-28 C+
ATI Allegheny Technologies Incorporated Q1 2018 2018-04-24 B
INST Instructure's Q4 2017 2018-02-12 B+
HOLX Hologic, Inc. Q4 2017 2017-11-08 D
GNTX Gentex Corporation Q3 2017 2017-10-20 B
MXL MaxLinear, Inc. Q2 2017 2017-08-08 C+
BIIB Biogen Inc. Q2 2017 2017-07-25 B
CNS Cohen & Steers, Inc. Q2 2017 2017-07-20 B
PTC PTC Inc. Q3 2017 2017-07-19 C+
PLAB Photronics, Inc. Q2 2017 2017-05-17 C+
IONS Ionis Pharmaceuticals, Inc. Q1 2017 2017-05-09 C
ICFI ICF International, Inc. Q1 2017 2017-05-06 B+
PPG PPG Industries, Inc. Q1 2017 2017-04-20 C
MDLZ Mondelez International, Inc. Q4 2016 2017-02-07 C
BP BP p.l.c. Q4 2016 2017-02-07 B+
NTCT NetScout Systems, Inc. Q2 2017 2016-10-27 D
F Ford Motor Company Q3 2016 2016-10-27 B+
MAT Mattel, Inc. Q3 2016 2016-10-19 C
NDSN Nordson Corporation Q3 2016 2016-08-23 A
VRNS Varonis Systems, Inc. Q2 2016 2016-08-09 B+
NWSA News Corporation Q2 2016 2016-08-08 C+
CGNX Cognex Corporation Q2 2016 2016-08-01 A
TRV The Travelers Companies, Inc. Q2 2016 2016-07-21 C+
LBTYK Liberty Global's Q1 2016 2016-05-10 C+
GOGO Gogo Inc. Q1 2016 2016-05-06 C+
ESE ESCO Technologies Inc. Q2 2016 2016-05-03 A
DD DuPont de Nemours, Inc. Q1 2016 2016-04-26 B+
HD The Home Depot, Inc. Q4 2015 2016-02-23 A
SAN Banco Santander, S.A. Q4 2015 2016-01-27 B
HXL Hexcel Corporation Q4 2015 2016-01-22 B+

How the model reasoned

ICFI · Q1 2017 → YESThe question is: Does management point to a growth-bearing development that they previously told investors to expect, and now it's arriving with current activity, but still early with most contributio...YES Management explicitly references the themes from their February 2017 full-year earnings call (only two months prior), noting that the January-February pickup they had highlighted there continued through March. They then point to concrete current-period activity: ICF Olson won over $75 million in new revenue since acquisition (neither firm could have won independently), added substantial new-account wins in Q1, and saw its qualified pipeline rise significantly above year-end 2016 levels. John Wasson confirms the new projects and retainers are now lining up, with strong Q1 wins and momentum from added staff. Sudhakar states they expect mid-single-digit growth this 2017 and sequential improvement, while reiterating confidence in the medium-term outlook. The language makes clear the ramp is still early—H2 comparisons and most of the contribution lie ahead—matching the three-part pattern for this growth-bearing development. No other item in the call satisfies all three criteria as cleanly.
HOLX · Q4 2017 → YESThe question is about whether management points to a growth-bearing development they previously told investors to expect, and now it's arriving with current activity, but still early. YES The transcript shows a clear three-part pattern for international growth. Management explicitly references its prior expectation: “while we thought that international would be a double-digit grower by 2018, we've actually delivered on that promise a year earlier than anticipated.” In the just-reported Q4, they confirm the development with concrete activity 17.5% international growth (excluding Cynosure and blood), the sixth consecutive quarter of double-digit growth for molecular internationally, and Panther shipments exceeding prior-year levels. They also state it is still early with most contribution ahead: “we've actually delivered on that promise a year earlier,” and they hope investors remember this 2017 success story as they evaluate Cynosure 2.
PTC · Q3 2017 → YESThe question is about whether management points to a growth-bearing development they previously told investors to expect, and now it's arriving with current activity, but still early. YES Management explicitly references its prior long-term growth ambition for IoT (30-40% bookings growth, consistent with the faster-growing IoT market) as part of its double-digit overall plan, which it had communicated as the target to achieve sustainable growth. In the current quarter, it confirms this is materializing with 40%+ of IoT bookings from customer expansions, six-figure deals growing sequentially and year-over-year, and specific closed expansions with leading food/beverage, aerospace/defense, and medical device companies, plus strong contribution from these. It further conveys the development remains early by noting customers are "generally still in the early days of their IoT journeys" with "adoption is gaining momentum" and "further stages" (e.g.

More from the question bank

Customers coming back on their ownEscape velocity out of a small baseCounterparties stepping up before the numberFresh evidence outrunning the reported numbeCash cost of the waitSequential re-ratingAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.